5-aminolevulinic acid patches for actinic keratosis
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
5-aminolevulinic acid patches (Alacare®, medac pharma) are licensed in combination with photodynamic therapy as a single dose treatment for up to 6 mild actinic keratosis lesions on hairless areas of the face and scalp.
Download the full review below to read more.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Semaglutide for type 2 diabetes
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Semaglutide (Ozempic®▼, Novo Nordisk) is a GLP1 receptor agonist (GLP1RA) indicated as an adjunct to diet and exercise for the treatment of adults with insufficiently controlled type 2 diabetes mellitus.
Download the full review below to read more.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Fluticasone, umeclidinium, and vilanterol (Trelegy Ellipta) for COPD
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Fluticasone furoate/umeclidinium bromide/vilanterol dry powder inhaler (Trelegy Ellipta®) is a fixed-dose triple combination of a corticosteroid (ICS), a long-acting anti-muscarinic (LAMA) and a long-acting beta-agonist (LABA) for relief of symptoms in adults with chronic obstructive pulmonary disease.
This review is older than 3 years and has been archived. To request a copy, contact nuth.nyrdtc.rxsupp@nhs.net.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation